On Monday, Pfizer and BioNTech announced that their coronavirus vaccine was more than 90% effective in preventing Covid-19 among those without evidence of prior infection
“I think we can see light at the end of the tunnel,” Pfizer Chairman and CEO Dr. Albert Bourla told CNBC’s Meg Tirell on “Squawk Box.” “I believe this is likely the most significant medical advance in the last 100 years, if you count the impact this will have in public health, global economy.”
The coronavirus pandemic has claimed over 1.2 million lives worldwide.
Pfizer’s findings were based on the first interim efficacy analysis conducted by an external Data Monitoring Committee from the phase three clinical study. By evaluating 94 confirmed Covid-19 infections among the trial’s 43,538 participants, the analysis was split between vaccinated individuals and those who received a placebo. The result showed a vaccine efficacy rate of above 90% at seven days after the second dose.
Stock markets skyrocketed on the news. Futures on the Dow Jones Industrial Average climbed +1,646 points. By late morning, the Dow was up +3.7%.
The RSI Oscillator for PFE moved out of oversold territory on April 19, 2024. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 48 similar instances when the indicator left oversold territory. In of the 48 cases the stock moved higher. This puts the odds of a move higher at .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 53 cases where PFE's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on May 01, 2024. You may want to consider a long position or call options on PFE as a result. In of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for PFE just turned positive on May 01, 2024. Looking at past instances where PFE's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .
PFE moved above its 50-day moving average on May 01, 2024 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PFE advanced for three days, in of 278 cases, the price rose further within the following month. The odds of a continued upward trend are .
The 10-day moving average for PFE crossed bearishly below the 50-day moving average on April 08, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PFE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
PFE broke above its upper Bollinger Band on May 01, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for PFE entered a downward trend on May 01, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.763) is normal, around the industry mean (5.632). P/E Ratio (74.919) is within average values for comparable stocks, (48.974). Projected Growth (PEG Ratio) (0.281) is also within normal values, averaging (3.004). Dividend Yield (0.060) settles around the average of (0.164) among similar stocks. P/S Ratio (2.674) is also within normal values, averaging (3.643).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. PFE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PFE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 74, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of vaccines and injectable biologic medicines
Industry PharmaceuticalsMajor